Nothing Special   »   [go: up one dir, main page]

AU2001235696A1 - Compositions useful for regulating parkin gene activity - Google Patents

Compositions useful for regulating parkin gene activity

Info

Publication number
AU2001235696A1
AU2001235696A1 AU2001235696A AU3569601A AU2001235696A1 AU 2001235696 A1 AU2001235696 A1 AU 2001235696A1 AU 2001235696 A AU2001235696 A AU 2001235696A AU 3569601 A AU3569601 A AU 3569601A AU 2001235696 A1 AU2001235696 A1 AU 2001235696A1
Authority
AU
Australia
Prior art keywords
compositions useful
gene activity
parkin gene
regulating
regulating parkin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001235696A
Inventor
Isabelle Arnould-Reguigne
Alexis Brice
Olga Corti
Alain Fournier
Hana Koutnikova
Catherine Prades
Laurent Pradier
Marie-Francoise Rosier-Montus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Aventis Pharma SA
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0001980A external-priority patent/FR2805266B1/en
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Aventis Pharma SA filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of AU2001235696A1 publication Critical patent/AU2001235696A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, at least partially, the activity of parkin.
AU2001235696A 2000-02-17 2001-02-15 Compositions useful for regulating parkin gene activity Abandoned AU2001235696A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0001980 2000-02-17
FR0001980A FR2805266B1 (en) 2000-02-17 2000-02-17 COMPOSITIONS FOR USE IN CONTROLLING PARKIN ACTIVITY
US19848900P 2000-04-18 2000-04-18
US60198489 2000-04-18
PCT/FR2001/000461 WO2001060857A2 (en) 2000-02-17 2001-02-15 Compositions useful for regulating parkin gene activity

Publications (1)

Publication Number Publication Date
AU2001235696A1 true AU2001235696A1 (en) 2001-08-27

Family

ID=26212182

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001235696A Abandoned AU2001235696A1 (en) 2000-02-17 2001-02-15 Compositions useful for regulating parkin gene activity

Country Status (14)

Country Link
US (2) US7132396B2 (en)
EP (1) EP1259606B1 (en)
KR (1) KR100811926B1 (en)
AT (1) ATE466083T1 (en)
AU (1) AU2001235696A1 (en)
BR (1) BR0108376A (en)
CA (1) CA2400256C (en)
CY (1) CY1111004T1 (en)
DE (1) DE60141948D1 (en)
IL (3) IL151211A0 (en)
MX (1) MXPA02007869A (en)
NO (1) NO20023914L (en)
NZ (1) NZ520802A (en)
WO (1) WO2001060857A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051902A1 (en) * 2001-12-14 2003-06-26 Incyte Genomics, Inc. Neurotransmission-associated proteins
US7927786B2 (en) * 2003-02-18 2011-04-19 Cedars-Sinai Medical Center Parkin interacting polypeptides and methods of use
ES2662846T3 (en) * 2007-09-11 2018-04-10 Cancer Prevention And Cure, Ltd. Identification of proteins in human serum indicative of pathologies of human lung tissues
CN109297780B (en) * 2018-10-23 2021-01-01 东华理工大学 Sampling method in liquid plastic limit combined determination method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500813A (en) * 1999-12-21 2004-01-15 インサイト・ゲノミックス・インコーポレイテッド Vesicle transport protein
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
US20030220240A1 (en) * 2000-12-21 2003-11-27 Tang Y. Tom Vesicle trafficking proteins

Also Published As

Publication number Publication date
IL151211A0 (en) 2003-04-10
WO2001060857A3 (en) 2002-06-20
US20020155577A1 (en) 2002-10-24
EP1259606A2 (en) 2002-11-27
WO2001060857A2 (en) 2001-08-23
IL151211A (en) 2010-05-31
KR20020089352A (en) 2002-11-29
CA2400256C (en) 2014-09-09
IL193310A (en) 2011-12-29
NZ520802A (en) 2005-02-25
IL193310A0 (en) 2011-08-01
DE60141948D1 (en) 2010-06-10
KR100811926B1 (en) 2008-03-10
MXPA02007869A (en) 2003-02-10
US7132396B2 (en) 2006-11-07
CA2400256A1 (en) 2001-08-23
US20060287230A1 (en) 2006-12-21
US8273548B2 (en) 2012-09-25
NO20023914L (en) 2002-10-11
CY1111004T1 (en) 2015-06-11
BR0108376A (en) 2003-03-11
EP1259606B1 (en) 2010-04-28
ATE466083T1 (en) 2010-05-15
NO20023914D0 (en) 2002-08-16

Similar Documents

Publication Publication Date Title
IL148243A0 (en) Trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and pharmaceutical compositions containing the same
WO2001064920A3 (en) Hybrid expression of neisserial proteins
AU3368497A (en) Human dnase i hyperactive variants
AU2845599A (en) Pharmaceutical compositions and their use
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
AUPP589598A0 (en) Novel peptides
WO2004054607A3 (en) Stable therapeutic proteins
AU4363199A (en) Use of hmg proteins for the preparation of medicaments having cytotoxic activity
AU2002212505A1 (en) Dna expression vectors
WO2001012661A3 (en) RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS
CY1111004T1 (en) USEFUL COMPOSITIONS FOR REGULATING PARKIN GENE ACTION
WO2003087353A3 (en) Purified polypeptides involved in membrane biogenesis
AU7525398A (en) Inhibitors for urokinase receptor
AU762955C (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
AUPO089396A0 (en) Neuroactive peptide
AU2002319236A1 (en) Method for the production of protamine
AU2003227622A1 (en) Methylthiophene carboxanilides
GB0221169D0 (en) Crystal
AU2001249267A1 (en) Methods and compositions for elucidating protein expression profiles in cells
WO2001066709A3 (en) Sphingomyelinase enzymes and uses relating thereto
WO2005105832A3 (en) Biologically active peptide vapeehptllteaplnpk derivatives
WO2004020457A3 (en) Methods and compositions for the inhibition of dna repair protein xrcc-3
AU2002249173A1 (en) Phosphorylated glyoxalase i and its use
WO2002012336A3 (en) TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE
WO2001023540A3 (en) P-glycoproteins and uses thereof